Key result
Ivabradine and metoprolol linked to a ~32% peak VO2 improvement in an IST and DCM case.
Why the study?
Managing LBBB and inappropriate sinus tachycardia in athletes is challenging because standard rate-control therapies like beta-blockers and ivabradine are typically associated with reduced maximal exercise performance.
Does combined ivabradine and beta-blocker therapy improve exercise tolerance and peak VO2 in a patient with inappropriate sinus tachycardia and mild dilated cardiomyopathy?
Case Report (n=1)
Does combined ivabradine and beta-blocker therapy improve exercise tolerance and peak VO2 in a patient with inappropriate sinus tachycardia and mild dilated cardiomyopathy?
Absolute Event Rate: 29.2% vs 22.1%
Combined ivabradine and beta-blocker therapy paradoxically improved exercise tolerance and peak VO2 in an athlete with inappropriate sinus tachycardia and mild dilated cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
May improve peak VO2 in select IST cases; leaves open efficacy of combined therapy in broader DCM populations.
Graziano et al. (2024) conducted a case report in Inappropriate sinus tachycardia and mild dilated cardiomyopathy (n=1). Ivabradine and metoprolol vs. Baseline (off-therapy) was evaluated on Peak oxygen consumption (VO2). Combined ivabradine and metoprolol therapy improved peak VO2 from 22.1 to 29.2 mL/kg/min in a patient with inappropriate sinus tachycardia and mild dilated cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: